Hepatology
Page 1 • 4 itemsGain critical insights into the global hepatology drug market. Track R&D, regulatory approvals, and investment opportunities in liver disease therapeutics.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
Novo Nordisk's Denecimig Shows Significant Bleeding Reduction in Hemophilia A Phase 3 Trial Published in NEJM
Denecimig (Mim8) significantly reduced annualized bleeding rates in hemophilia A patients regardless of inhibitor status in pivotal FRONTIER2 study.
Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Hemophilia A Stem Cell Therapy
Expression Therapeutics gains dual FDA designations for investigational autologous stem cell therapy targeting hemophilia A, advancing to Phase 2 trials.